Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 7/20 | 0.42 |
| ▸ | CNR2 | P34972 | 5/20 | 0.31 |
| ▸ | CNR1 | P21554 | 4/20 | 0.31 |
| ▸ | VNN1 | O95497 | 3/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12927947 | 0.92 | TTK (0.46) | TTKCNR2 | |
| SCHEMBL105613 | 0.88 | TTK (0.36) | TTKCNR2CNR1 | |
| SCHEMBL104174 | 0.88 | CDK9 (0.33) | TTKCNR2CNR1CDK9 | |
| SCHEMBL10282480 | 0.88 | TTK (0.32) | TTKCNR2CNR1CDK9 | |
| SCHEMBL104960 | 0.83 | TTK (0.41) | TTKCNR2CNR1 | |
| SCHEMBL104841 | 0.82 | TTK (0.38) | TTKCNR2CNR1VNN1 | |
| SCHEMBL139927 | 0.82 | TTK (0.47) | TTKCNR2CNR1 | |
| SCHEMBL104135 | 0.82 | TTK (0.68) | TTK | |
| SCHEMBL104290 | 0.81 | TTK (0.30) | TTK | |
| SCHEMBL13193075 | 0.79 | CNR2 (0.30) | CNR2CNR1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | TTK 6/4885CNR2 1750/4885CNR1 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.